NF1 alterations in cancers: therapeutic implications in precision medicine.
Jean-Stéphane GiraudIvan BiècheÉric PasmantCamille TlemsaniPublished in: Expert opinion on investigational drugs (2023)
gene. Currently, most studies are focusing on inhibitors of the RAS/MAPK and PI3K-AKT-mTOR pathways and immunotherapies.